Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Dec 15;90(24):11924–11928. doi: 10.1073/pnas.90.24.11924

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

T Tamura 1, N Udagawa 1, N Takahashi 1, C Miyaura 1, S Tanaka 1, Y Yamada 1, Y Koishihara 1, Y Ohsugi 1, K Kumaki 1, T Taga 1, et al.
PMCID: PMC48097  PMID: 8265649

Abstract

It has been reported that soluble interleukin (IL)-6 receptor (sIL-6R) is detected in the serum of healthy individuals and its level is increased in patients with multiple myeloma and human immunodeficiency virus infection. Although several reports have suggested that sIL-6R potentiates IL-6 action, its physiological role remains unclear. In this study, we examined the role of sIL-6R on osteoclast formation by IL-6, using a coculture of mouse osteoblasts and bone marrow cells. Neither recombinant mouse IL-6 (mIL-6) nor mouse sIL-6R (smIL-6R) induced osteoclast-like multinucleated cell (MNC) formation when they were added separately. In contrast, simultaneous treatment with mIL-6 and smIL-6R strikingly induced MNC formation. These MNCs satisfied major criteria of authentic osteoclasts, such as tartrate-resistant acid phosphatase (TRAP) activity, calcitonin receptors, and pit formation on dentine slices. The MNC formation induced by mIL-6 and smIL-6R was dose-dependently inhibited by adding monoclonal anti-mouse IL-6R antibody (MR16-1). It is likely that osteoblasts and osteoclast progenitors are capable of transducing a signal from a complex of IL-6 and sIL-6R through gp130, even though they may have no or a very small number of IL-6Rs. Factors such as IL-11, oncostatin M, and leukemia inhibitory factor, which are known to exert their functions through gp130 (the signal-transducing chain of IL-6R), also induced MNC formation in our coculture system. These results suggest that increased circulating or locally produced sIL-6R induces osteoclast formation in the presence of IL-6 mediated by a mechanism involving gp130. This may play an important physiological or pathological role in conditions associated with increased osteoclastic bone resorption.

Full text

PDF
11924

Images in this article

11926Fig. 1
on p.11926
11926Fig. 3
on p.11926
11927Fig. 4
on p.11927
11927Fig. 5
on p.11927

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akatsu T., Takahashi N., Debari K., Morita I., Murota S., Nagata N., Takatani O., Suda T. Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3',5'-monophosphate in mouse bone marrow cell cultures. J Bone Miner Res. 1989 Feb;4(1):29–35. doi: 10.1002/jbmr.5650040106. [DOI] [PubMed] [Google Scholar]
  2. Akatsu T., Takahashi N., Udagawa N., Imamura K., Yamaguchi A., Sato K., Nagata N., Suda T. Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. J Bone Miner Res. 1991 Feb;6(2):183–189. doi: 10.1002/jbmr.5650060212. [DOI] [PubMed] [Google Scholar]
  3. Akatsu T., Takahashi N., Udagawa N., Sato K., Nagata N., Moseley J. M., Martin T. J., Suda T. Parathyroid hormone (PTH)-related protein is a potent stimulator of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse marrow cultures. Endocrinology. 1989 Jul;125(1):20–27. doi: 10.1210/endo-125-1-20. [DOI] [PubMed] [Google Scholar]
  4. Akatsu T., Tamura T., Takahashi N., Udagawa N., Tanaka S., Sasaki T., Yamaguchi A., Nagata N., Suda T. Preparation and characterization of a mouse osteoclast-like multinucleated cell population. J Bone Miner Res. 1992 Nov;7(11):1297–1306. doi: 10.1002/jbmr.5650071109. [DOI] [PubMed] [Google Scholar]
  5. Barton B. E., Mayer R. IL 3 and IL 6 do not induce bone resorption in vitro. Cytokine. 1990 May;2(3):217–220. doi: 10.1016/1043-4666(90)90019-p. [DOI] [PubMed] [Google Scholar]
  6. Black K., Garrett I. R., Mundy G. R. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991 May;128(5):2657–2659. doi: 10.1210/endo-128-5-2657. [DOI] [PubMed] [Google Scholar]
  7. Gaillard J. P., Bataille R., Brailly H., Zuber C., Yasukawa K., Attal M., Maruo N., Taga T., Kishimoto T., Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol. 1993 Apr;23(4):820–824. doi: 10.1002/eji.1830230408. [DOI] [PubMed] [Google Scholar]
  8. Girasole G., Jilka R. L., Passeri G., Boswell S., Boder G., Williams D. C., Manolagas S. C. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992 Mar;89(3):883–891. doi: 10.1172/JCI115668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Maini R., Feldmann M. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988 Nov;18(11):1797–1801. doi: 10.1002/eji.1830181122. [DOI] [PubMed] [Google Scholar]
  10. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol. 1992 Apr 1;148(7):2175–2180. [PubMed] [Google Scholar]
  11. Ishimi Y., Miyaura C., Jin C. H., Akatsu T., Abe E., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990 Nov 15;145(10):3297–3303. [PubMed] [Google Scholar]
  12. Jilka R. L., Hangoc G., Girasole G., Passeri G., Williams D. C., Abrams J. S., Boyce B., Broxmeyer H., Manolagas S. C. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992 Jul 3;257(5066):88–91. doi: 10.1126/science.1621100. [DOI] [PubMed] [Google Scholar]
  13. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  14. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992 Oct 23;258(5082):593–597. doi: 10.1126/science.1411569. [DOI] [PubMed] [Google Scholar]
  15. Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
  16. Littlewood A. J., Russell J., Harvey G. R., Hughes D. E., Russell R. G., Gowen M. The modulation of the expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology. 1991 Sep;129(3):1513–1520. doi: 10.1210/endo-129-3-1513. [DOI] [PubMed] [Google Scholar]
  17. Löwik C. W., van der Pluijm G., Bloys H., Hoekman K., Bijvoet O. L., Aarden L. A., Papapoulos S. E. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun. 1989 Aug 15;162(3):1546–1552. doi: 10.1016/0006-291x(89)90851-6. [DOI] [PubMed] [Google Scholar]
  18. Mackiewicz A., Schooltink H., Heinrich P. C., Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol. 1992 Sep 15;149(6):2021–2027. [PubMed] [Google Scholar]
  19. Novick D., Engelmann H., Wallach D., Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989 Oct 1;170(4):1409–1414. doi: 10.1084/jem.170.4.1409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Roodman G. D. Interleukin-6: an osteotropic factor? J Bone Miner Res. 1992 May;7(5):475–478. doi: 10.1002/jbmr.5650070502. [DOI] [PubMed] [Google Scholar]
  21. Saito T., Yasukawa K., Suzuki H., Futatsugi K., Fukunaga T., Yokomizo C., Koishihara Y., Fukui H., Ohsugi Y., Yawata H. Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies. J Immunol. 1991 Jul 1;147(1):168–173. [PubMed] [Google Scholar]
  22. Suda T., Takahashi N., Martin T. J. Modulation of osteoclast differentiation. Endocr Rev. 1992 Feb;13(1):66–80. doi: 10.1210/edrv-13-1-66. [DOI] [PubMed] [Google Scholar]
  23. Suzuki H., Yasukawa K., Saito T., Narazaki M., Hasegawa A., Taga T., Kishimoto T. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol. 1993 May;23(5):1078–1082. doi: 10.1002/eji.1830230515. [DOI] [PubMed] [Google Scholar]
  24. Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989 Aug 11;58(3):573–581. doi: 10.1016/0092-8674(89)90438-8. [DOI] [PubMed] [Google Scholar]
  25. Taga T., Kishimoto T. Role of a two-chain IL-6 receptor system in immune and hematopoietic cell regulation. Crit Rev Immunol. 1992;11(5):265–280. [PubMed] [Google Scholar]
  26. Takahashi N., Akatsu T., Udagawa N., Sasaki T., Yamaguchi A., Moseley J. M., Martin T. J., Suda T. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988 Nov;123(5):2600–2602. doi: 10.1210/endo-123-5-2600. [DOI] [PubMed] [Google Scholar]
  27. Takahashi N., Yamana H., Yoshiki S., Roodman G. D., Mundy G. R., Jones S. J., Boyde A., Suda T. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology. 1988 Apr;122(4):1373–1382. doi: 10.1210/endo-122-4-1373. [DOI] [PubMed] [Google Scholar]
  28. Tamura T., Takahashi N., Akatsu T., Sasaki T., Udagawa N., Tanaka S., Suda T. New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro. J Bone Miner Res. 1993 Aug;8(8):953–960. doi: 10.1002/jbmr.5650080808. [DOI] [PubMed] [Google Scholar]
  29. Yasukawa K., Saito T., Fukunaga T., Sekimori Y., Koishihara Y., Fukui H., Ohsugi Y., Matsuda T., Yawata H., Hirano T. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem. 1990 Oct;108(4):673–676. doi: 10.1093/oxfordjournals.jbchem.a123261. [DOI] [PubMed] [Google Scholar]
  30. Yin T., Taga T., Tsang M. L., Yasukawa K., Kishimoto T., Yang Y. C. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol. 1993 Sep 1;151(5):2555–2561. [PubMed] [Google Scholar]
  31. Yoneda T., Nakai M., Moriyama K., Scott L., Ida N., Kunitomo T., Mundy G. R. Neutralizing antibodies to human interleukin 6 reverse hypercalcemia associated with a human squamous carcinoma. Cancer Res. 1993 Feb 15;53(4):737–740. [PubMed] [Google Scholar]
  32. al-Humidan A., Ralston S. H., Hughes D. E., Chapman K., Aarden L., Russell R. G., Gowen M. Interleukin-6 does not stimulate bone resorption in neonatal mouse calvariae. J Bone Miner Res. 1991 Jan;6(1):3–8. doi: 10.1002/jbmr.5650060103. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES